Vamikibart  (Synonyms: EBI-031)

Vamikibart (RG6179) is a monoclonal antibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition^[1][2].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

IL-6/IFNb2

3569  [NCBI]

P05231

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.96 kDa

2744320-12-3

Liquid

Colorless to light yellow

[Vamikibart]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Immobilized IL-6 Protein, Human can bind Vamikibart. The EC₅₀ for this effect is 21.6 ng/mL.
• 
  Flow cytometric analysis of 1.5×10⁶ Siha cells labeling Vamikibart (HY-P990012, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa Isotype Control (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Sharma, et al. Longitudinal Quantitative Anterior Chamber Cell Analysis Following Vamikibart Intravitreal Therapy in Patients with Uveitic Macular Edema from the DOVETAIL Clinical Trial. Investigative Ophthalmology & Visual Science 65.7 (2024): 3028-3028.

  [2]. Cakir, et al. Longitudinal quantitative ultra-widefield fluorescein angiography leakage dynamics in patients with uveitic macular edema following intravitreal anti-IL-6 therapy with vamikibart. Investigative Ophthalmology & Visual Science 65.7 (2024): 2628-2628.